Home / Innere Medizin / Onkologie / ESMO 2018: An oral FGFR inhibitor for head and neck cancer
Prof. DDr. Markus Jörger

ESMO 2018: An oral FGFR inhibitor for head and neck cancer

PD DDr. Markus Jörger, Department for Medical Oncology and Hematology of Kantonsspital St.Gallen on a phase I trial investigating the treatment of head and neck cancer with rogaratinib, an oral FGFR inhibitor.

Interviewpartner:

Redaktion:

Produktion:

Source: ESMO 2018 Congress

Joerger M et al., Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression. Abstract #1056PD

LOGIN

Login

Passwort vergessen?